Patents by Inventor Richard E. Olson

Richard E. Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tau antisense oligomers and uses thereof
    Patent number: 10799523
    Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: October 13, 2020
    Assignee: F. HOFFMANN-LA ROCHE AG
    Inventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Dong Li, Jeffrey M. Brown, Marianne Lerbech Jensen, Niels Fisker Nielsen, Stephen E. Mercer
  • Substituted naphthyridinone compounds useful as T cell activators
    Patent number: 10669272
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: June 2, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20200109140
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: June 26, 2019
    Publication date: April 9, 2020
    Inventors: Upender VELAPARTHI, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
    Publication number: 20200010831
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 9, 2020
    Applicant: Hoffmann-La Roche, Inc.
    Inventors: Peter HAGEDORN, Anja Mølhart HØG, Marianne L. JENSEN, Richard E. Olson
  • Methods of Selecting Therapeutic Molecules
    Publication number: 20190383797
    Abstract: The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.
    Type: Application
    Filed: February 4, 2016
    Publication date: December 19, 2019
    Inventors: Richard E. OLSON, Angela M. CACACE, Peter HAGEDORN, Anja Mølhart HØG, Niels Fisker NIELSEN, Dong LI, Jeffrey M. BROWN, Stephen E. MERCER, Marianne Lerbech JENSEN
  • NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS
    Publication number: 20190322694
    Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 24, 2019
    Inventors: Michael Anthony SCHMIDT, Bin ZHENG, Kyle KNOUSE, Justine deGRUYTER, Martin D. EASTGATE, Phil BARAN, William R. EWING, Richard E. OLSON, Ivar M. McDONALD
  • CAMK2D ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
    Publication number: 20190275148
    Abstract: The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.
    Type: Application
    Filed: February 21, 2019
    Publication date: September 12, 2019
    Inventors: Richard E. Olson, Brian R. Anderson, Peter Hagedorn, Marianne Lerbech Jensen, Ivar M. McDonald, Stephen E. Mercer
  • TAU ANTISENSE OLIGOMERS AND USES THEREOF
    Publication number: 20180161356
    Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: February 4, 2016
    Publication date: June 14, 2018
    Inventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Marianne Lerbech Jensen, Niels Fisker Nielsen, Dong Li, Jeffrey M. Brown, Stephen E. Mercer
  • LNA OLIGONUCLEOTIDES WITH ALTERNATING FLANKS
    Publication number: 20180023081
    Abstract: The present invention relates to LNA oligomers having two flanks, wherein one or both flanks comprise alternating LNA and DNA nucleosides.
    Type: Application
    Filed: February 4, 2016
    Publication date: January 25, 2018
    Inventors: Peter HAGEDORN, Richard E. OLSON, Anja Mølhart HØG, Marianne Lerbech JENSEN, Dong LI, Niels Fisker NIELSEN
  • Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production
    Patent number: 9833454
    Abstract: The compound N2-(3-(difluoromethoxy)-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N4,5,5-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine: [PLEASE INSERT CHEMICAL STRUCTURE HERE] reduces -amyloid peptide (A 42) production and has low potential for bioactivation, and may be useful in the treatment of Alzheimer's Disease and other conditions affected by -amyloid peptide (A 42) production.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: December 5, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Stephen E. Mercer, Richard E. Olson, Xiaoliang Zhou
  • Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
    Patent number: 9796713
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: October 24, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ivar M. McDonald, Richard E. Olson, Robert A. Mate
  • Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
    Patent number: 9708323
    Abstract: The disclosure provides compounds of formula I including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: July 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ivar M. McDonald, F. Christopher Zusi, Richard E. Olson
  • DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
    Publication number: 20170182050
    Abstract: The compound N2-(3-(difluoromethoxy)-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N4,5,5-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine: [PLEASE INSERT CHEMICAL STRUCTURE HERE] reduces -amyloid peptide (A 42) production and has low potential for bioactivation, and may be useful in the treatment of Alzheimer's Disease and other conditions affected by -amyloid peptide (A 42) production.
    Type: Application
    Filed: April 1, 2015
    Publication date: June 29, 2017
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Stephen E. Mercer, Richard E. Olson, Xiaoliang Zhou
  • TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
    Publication number: 20170137425
    Abstract: The disclosure provides compounds of formula I including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Application
    Filed: June 5, 2015
    Publication date: May 18, 2017
    Inventors: Ivar M. MCDONALD, F. Christopher ZUSI, Richard E. OLSON
  • TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
    Publication number: 20170129892
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Application
    Filed: June 5, 2015
    Publication date: May 11, 2017
    Inventors: Ivar M. MCDONALD, Richard E. OLSON, Robert A. MATE
  • Tau Antisense Oligomers and Uses Thereof
    Publication number: 20160237427
    Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: February 4, 2016
    Publication date: August 18, 2016
    Inventors: Richard E. OLSON, Angela M. CACACE, Peter HAGEDORN, Anja Mølhart HØG, Marianne Lerbech JENSEN, Niels Fisker NIELSEN, Dong LI, Jeffrey M. BROWN, Stephen E. MERCER
  • Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
    Patent number: 9403776
    Abstract: The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): where the carbon atom designated * is in the R or S configuration, and the substituents X and R1-R9 are as defined herein.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: August 2, 2016
    Assignee: Albany Molecular Research, Inc.
    Inventors: Bruce F. Molino, Shuang Liu, Aruna Sambandam, Peter R. Guzzo, Min Hu, Congxiang Zha, Kassoum Nacro, David D. Manning, Matthew L. Isherwood, Kristen N. Ryan, Wenge Cui, Richard E. Olson
  • QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
    Publication number: 20160101104
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Inventors: James H. Cook, II, Ivar M. McDonald, Dalton King, Richard E. Olson, Nenghui Wang, Christiana I. lwuagwu, F. Christopher Zusi, John E. Macor
  • QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
    Publication number: 20150342935
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Application
    Filed: August 6, 2015
    Publication date: December 3, 2015
    Inventors: James H. Cook, II, Ivar M. McDonald, Dalton King, Richard E. Olson, Nenghui Wang, Christiana I. Iwuagwu, F. Christopher Zusi, John E. Macor
  • COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
    Publication number: 20150336975
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Application
    Filed: August 3, 2015
    Publication date: November 26, 2015
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev